Treatment with the anti-PD1 antibody pidilizumab in DLBCL patients who had measurable disease after autologous hematopoietic stem cell transplant resulted in an overall response rate of 51% [60]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.